OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors

Core Insights - OmniAb has entered into a technology license and services agreement with Mabtrx Biosciences, a subsidiary of a joint venture between ArrowMark Partners and Viking Global Investors, focusing on antibody discovery programs [1][2][3] Company Overview - OmniAb specializes in licensing advanced discovery research technology to pharmaceutical and biotech companies, enabling the identification of next-generation therapeutics [8] - The company's technology platform utilizes engineered transgenic animals to create optimized antibody candidates, claiming to have the most diverse host systems in the industry [8] Financial Aspects - Under the new agreement, OmniAb will receive revenue for services, potential equity, and royalties from the discovery of novel antibodies for targets defined by Mabtrx [2][3] Strategic Partnerships - The collaboration with ArrowMark and Viking is seen as a strategic move to leverage OmniAb's unique technologies for value creation in drug discovery [3] - ArrowMark Partners is known for its focus on niche market segments and has a history of successful biotech investments [4] - Viking Global Investors manages over $55 billion in capital and employs a long-term, research-intensive investment approach [5]